BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Metrics to compare | BLRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.1x | −2.5x | −0.7x | |
PEG Ratio | −0.02 | 0.04 | 0.00 | |
Price/Book | 0.8x | 2.5x | 2.6x | |
Price / LTM Sales | 1.0x | 19.3x | 3.4x | |
Upside (Analyst Target) | - | 170.5% | 37.6% | |
Fair Value Upside | Unlock | 13.0% | 4.6% | Unlock |